Study directory

Mental health studies with practical context.

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
10612studies shown
Showing 2,617-2,628 of 10,612
Drug study icon
CompletedNCT03227224

JNJ-42847922 for depression

This study is completed in the United States, in France, in Bulgaria, .... It is testing JNJ-42847922 for depression.

In United States
DepressionDrugA study involving a medication or substance.From 18 Years to 70 Years
Countries
United States, France, Bulgaria, ...
Sponsor
Janssen Research & Development, LLC
Condition
Depression
Drug study icon
CompletedNCT06267846

NBI-1070770 for depression

This study is completed in the United States. It is testing NBI-1070770 for depression.

In United States
DepressionDrugFrom 18 Years to 65 Years
Countries
United States
Sponsor
Neurocrine Biosciences
Condition
Depression
Drug study icon
CompletedNCT02969382

SEP-363856 for schizophrenia

This study is completed in the United States, in Hungary, in Romania, .... It is testing SEP-363856 for schizophrenia.

In United States
SchizophreniaDrugFrom 18 Years to 40 Years
Countries
United States, Hungary, Romania, ...
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
Drug study icon
CompletedNCT01364662

SPN-810 for ADHD

This study is completed in the United States. It is testing SPN-810 for ADHD.

In United States
ADHDDrugFrom 6 Years to 12 Years
Countries
United States
Sponsor
Supernus Pharmaceuticals, Inc.
Condition
ADHD
Drug study icon
CompletedNCT00531752

Two Doses of PF-03654746 for ADHD

This study is completed in the United States. It is testing Two Doses of PF-03654746 for ADHD.

In United States
ADHDDrugFrom 18 Years to 55 Years
Countries
United States
Sponsor
Pfizer
Condition
ADHD
Drug study icon
CompletedNCT02969369

Safety study of SEP-363856 in Schizophrenia

This study is completed in the United States. It is testing SEP-363856 for Schizophrenia.

In United States
SchizophreniaDrugFrom 55 Years to 105 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
Drug study icon
CompletedNCT02417064

Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant for treatment-resistant depression

This study is completed in the United States, in France, in Canada, .... It is testing efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant for treatment-resistant depression.

In United States
DepressionDrugFrom 18 Years to 64 Years
Countries
United States, France, Canada, ...
Sponsor
Janssen Research & Development, LLC
Condition
Depression
Drug study icon
CompletedNCT02418585

Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant for treatment-resistant depression

This study is completed in the United States, in Czechia, in Germany, .... It is testing efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant for treatment-resistant depression.

In United States
DepressionDrugFrom 18 Years to 64 Years
Countries
United States, Czechia, Germany, ...
Sponsor
Janssen Research & Development, LLC
Condition
Depression
Drug study icon
CompletedNCT02422186

Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant for treatment-resistant depression

This study is completed in the United States, in France, in the United Kingdom, .... It is testing efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant for treatment-resistant depression.

In United States
DepressionDrugOver 65 Years
Countries
United States, France, United Kingdom, ...
Sponsor
Janssen Research & Development, LLC
Condition
Depression
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.